10.1038/nm.4324 [DOI] [PMC free article] [PubMed] [Google Scholar] 24.Baar MP, Brandt RMC, Putavet DA, Klein JDD, Derks KWJ, Bourgeois BRM, Stryeck S, Rijksen Y, van Willigenburg H, Feijtel DA, van der Pluijm I, Essers J, van Cappellen WA, et al
That said, some companies skirt the law by labeling BPC157 as a research chemical not for human use. While technically not illegal to possess in this form, it's a legal gray areaand the FDA has already sent warning letters to vendors marketing it for recovery or performance purposes
USA , 91 , 1173311737
Bimekizumab has demonstrated rapid and clinical improvements in joint and skin efficacy outcomes to 52 weeks, with high levels of response observed among patients with active PsA who were biologic disease-modifying antirheumatic drug (bDMARD)-nave or had inadequate response or intolerance to tumor necrosis factor inhibitors (TNFi-IR)